Delivering unique therapeutic and R&D monoclonal antibodies against membrane receptors and haptens

SYnAbs generates innovative monoclonal antibodies against:

• haptens (carbohydrates, small molecules, small peptides, lipids...)
• highly homologous antigens (epigenetic modifications,...)
• and complex transmembrane proteins.

SYnAbs unique technologies (SYnDNA vector, SYnCell syngeneic cell, in-house adjuvant) coupled with its strong expertise in breaking immune tolerance in proprietary rat-LOU species, ensure the generation of high specificity and higher affinity antibodies, benefiting from natural in-vivo maturation and targeting epitopes that are difficult to express in their native and functionally active conformation.

The application of such technologies have led, among others, to the generation of numerous functional therapeutic antibodies like : 

• LO-CD2a Siplizumab (licensed to MedImmune, MEDI-507)
• LO-CD2b
• LO-TACT-1, anti-CD25 
• SYnCCR8, therapeutic mAb against hCCR8 GPCR
• SYnC3aR, therapeutic blocking mAb against hC3aR GPCR anaphylatoxin receptor

Time to enjoy your free ebook :

"Proven strategies for successful antibodies generation against difficult antigens"

Le projet MENAC a pour objectif de développer de tests innovants non invasifs pour la détection précoce 

de différents types de cancers.

Ce projet réalisé en partenariat par les sociétés Volition et Synabs passe par la création d'anticorps monoclonaux 

et la mise au point de nouveaux immuno-essais diagnostiques et théranostiques.

Subvention de 1.990.798€